This powerful drug combo cuts prostate cancer deaths by 40%

Cancer research · Prostate cancer

Adding enzalutamide to standard hormone therapy can cut the risk of death by more than 40% in men with high‑risk biochemically recurrent prostate cancer.

Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.

Original source

Related signals

• Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
• The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
• The contemporary management of prostate cancer
• Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
• Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience